Daniel Soland


Daniel Soland has served as a director of Acadia since March 2015.

Mr. Soland formerly served as the Senior Vice President and Chief Operating Officer at Idera Pharmaceuticals. He previously served as Chief Executive Officer of uniQure N.V., a human gene therapy company, from December 2015 through September 2016. He served as Senior Vice President and Chief Operating Officer of ViroPharma starting in 2008 until it was acquired by Shire in 2014, and as Vice President and Chief Commercial Officer of ViroPharma from 2006 to 2008.

During his tenure at ViroPharma, Mr. Soland managed the commercial, manufacturing and quality organizations, helped build the company’s commercial infrastructure in the United States, Europe and Canada, and led the launch of Cinryze®, one of the most successful ultra-orphan drugs in the United States. Mr. Soland served as President, Chiron Vaccines, of Chiron Corporation from 2005 to 2006 and led the growth of the vaccine business to over $1 billion in sales.

From 2002 through 2005, Mr. Soland served as President and Chief Executive Officer of Epigenesis Pharmaceuticals. Earlier in his career, Mr. Soland worked for GlaxoSmithKline in increasing roles of responsibility from 1993 to 2002, including as Vice President and Director, Worldwide Marketing Operations, GSK Biologicals.

He currently serves on the board of directors of DBV Technologies SA. Mr. Soland earned his B.S. in Pharmacy from the University of Iowa.